Automating Lab Data Analysis to Accelerate Biopharma R&D

November 12, 2025

Labs increasingly automate experimental execution to increase throughput and minimize manual effort. Raw data generation is just the starting point. To capture the full value of automation, labs must streamline complex assay analysis. 

In modern discovery workflows, advanced technologies, such as phenotypic screens, mechanistic assays, and biophysical methods, generate rich, multiparameter datasets earlier in the process. These data deliver deeper insights and fuel predictive AI models, accelerating the identification of promising therapeutic candidates. By enabling earlier use of information-rich assays, labs can reduce downstream risk and uncover novel therapeutic candidates.

But scaling analysis across these datasets introduces a major challenge. Manual interpretation slows workflows and limits the impact of even the most innovative assays.

The first post in this series examined how automating data capture and transfer maximizes ROI from lab automation hardware. This second post focuses on the next step: automating data analysis for complex assays, illustrated with real-world examples from Genedata.

Challenges in Complex Lab Data Analysis for Biopharma R&D

As biopharmaceutical R&D advances, lab data grows increasingly complex. Manual methods no longer deliver the speed, accuracy, and consistency required to support high-throughput, data-driven discovery. 

Integrating Complex, Multimodal Data

High-throughput assay technologies, including high-content imaging, mechanistic kinetic assays, and surface plasmon resonance (SPR), generate complex, multi-dimensional datasets. Consolidating outputs from diverse instruments and formats introduces inefficiencies and increases the risk of error.

Scaling Analysis Across High-Throughput Workflows

High-throughput screens generate thousands of data points per run. To maintain efficiency at scale, labs must automate analysis. Manual methods consume resources and slow discovery. 

Ensuring Consistent, High-Quality Results

Manual interpretation introduces variability across teams and sites, undermining reproducibility. Inconsistent labeling and subjective analysis degrade AI algorithm performance. Genedata studies show that misclassified training data significantly reduces model accuracy, reinforcing the need for standardized, automated workflows. 

Examples of Complex Lab Data: Kinetic, SPR, HCS, MS

Complex assays generate rich, multiparameter datasets that reveal drug-target interactions, phenotypic effects, and molecular behavior. However, analyzing these datasets at scale introduces significant challenges. The following examples highlight the analytical complexity of modern lab data.

1. Mechanistic Kinetic Assays

   These assays reveal how a candidate compound interacts with its target, whether through a one-step or two-step binding process, or via competitive, noncompetitive or uncompetitive inhibition. This mechanistic insight goes beyond potency or efficacy, helping scientists prioritize candidates with desirable features, such as slow-binding profiles that may improve efficacy and reduce off-target effects. 
   
   To support early-stage mechanistic studies, companies such as AstraZeneca have developed high-throughput assays using systems including FLIPR Tetra, which captures data from an entire plate in a single read. Yet even with optimized assay platforms, analyzing kinetic data remains complex. Scientists must assess raw data quality, select appropriate models, and evaluate model fit. These decisions require expertise and are difficult to scale manually.

2. Surface Plasmon Resonance (SPR)

   SPR is a label-free, time-resolved method for quantifying molecular interactions. It provides detailed kinetic and affinity data, including binding strength, stoichiometry, and protein concentration. Once reserved for late-stage characterization due to low-throughput, SPR now plays a role earlier in discovery workflows, enabled by advances in instrumentation. High-throughput formats support its use even during primary screening, where biophysical approaches help tackle challenging targets.
   
   Quality control often requires visual inspection of SPR sensorgrams, selection of appropriate fit models, and manual annotation. These steps are subjective and time-consuming, especially across large datasets. Automation is essential to ensure consistency and scalability.

3. High-Content Screening (HCS)
   HCS enables phenotypic profiling across multiple endpoints using physiologically relevant cellular models. Multiplexed approaches such as Cell Painting generate hundreds of features per image, producing rich but complex datasets. These profiles can be compared against tool compounds with known modes of action (MOA) to infer mechanisms and prioritize candidates.
   
   AI-based analysis is commonly used to interpret these images, but training algorithms requires large, accurately labeled datasets. Manual classification and annotation limit scalability and reproducibility.
    

4. Mass Spectrometry (MS)

   MS is a label-free technique that quantifies ionized analytes based on mass-to-charge ratio. It enables simultaneous assessment of hundreds of compounds in a single reaction, supporting innovative assay designs and early-stage insights.
   
   MS datasets often contain tens of thousands of peaks, with significant sample-to-sample variation. Accurate quantification requires careful signal processing, peak identification, and clustering: tasks that are impractical to perform manually at high throughput. 

These examples highlight a common theme: while modern assays generate valuable insights, the complexity and scale of the resulting data make manual analysis impractical. Without automation, labs struggle to maintain consistency, throughput, and data quality, limiting the impact of even the most advanced technologies.

Automating lab data analysis transforms how results are processed, interpreted, and applied, unlocking the full potential of modern assay technologies.

How Automation Transforms Lab Data Analysis

Automation addresses the challenges outlined above through scalable, standardized, and efficient workflows. Key benefits include accelerated research cycles, improved data accuracy, and enhanced compliance through traceable, version-controlled processes.

Speed and Throughput Gains

Automated pipelines dramatically reduce analysis timelines, turning processes that once required hours or days into minutes. By integrating scalable data workflows with high-throughput screening, automation enables labs to process large sample volumes without bottlenecks.

Data Accuracy and Quality Control

Automated systems apply parameters consistently, eliminating variability and reducing human error. They detect anomalies, flag outliers, and apply standardized models across experiments, enhancing accuracy and reliability.

Reproducibility and Traceability

Automated workflows provide version-controlled pipelines and complete audit trails, ensuring reproducibility across teams and studies. They also enable full traceability through change logs, metadata tracking, and automated documentation.

Automated Lab Data Analysis with Genedata Screener

Automation delivers measurable benefits, but only when supported by scientifically validated, purpose-built solutions. Genedata Screener^® streamlines lab data analysis and transforms raw assay outputs into actionable insights with speed, consistency, and precision.

Automated Data Upload

Genedata Screener captures raw data directly from a wide range of instruments,  regardless of format or vendor. This eliminates manual transfers, prevents transcription errors, and ensures compatibility with high-throughput workflows.

Real-Time Analysis and Performance Monitoring

Once data is uploaded, Genedata Screener performs real-time analysis to deliver immediate insights. Dashboards and performance metrics provide continuous visibility into experiment progress, accelerating troubleshooting and optimization.

Automated Reporting and Documentation

Genedata Screener automatically generates standardized reports with visual summaries, statistical outputs, and key metrics. It also streamlines documentation for compliance with regulatory agencies such as the FDA and the EMA, using customizable templates that integrate seamlessly into existing systems.

Seamless Integration with Lab Workflows

Genedata Screener integrates directly with industry-standard lab instruments, electronic lab notebooks (ELNs), and laboratory information management systems (LIMS). With support for APIs and automation frameworks, it scales with evolving lab needs while minimizing disruption to existing workflows.

Accelerating Complex Assay Analysis with Genedata Screener: 30 Hours to 30 Minutes

Automating complex data analysis is not only possible — it’s already transforming workflows. Through close collaboration with leading biopharma companies, Genedata has developed scalable workflows that continue to reduce analysis time, improve objectivity, and ensure consistent, high-quality results across diverse assay types.

Biochemical Kinetic Assays

In partnership with AstraZeneca, Genedata developed a multistage, automated workflow within Genedata Screener for biochemical kinetic assays. User-defined standards and empirically determined criteria guide each step, ensuring consistency and scientific rigor. Key steps in the automated workflow include:

• Determine the optimal time window for analysis based on control data
• Verify that raw progress curves fall within the reliable signal detection range
• Exclude suspicious outliers to improve data integrity
• Select the optimal mechanistic model from validated options using statistical evaluation
• Annotate each compound with its respective model and flag any unreliable results

This automation reduced full-deck screen analysis time from 30 hours to just 30 minutes, while significantly improving objectivity, consistency, and robustness across the dataset.

Surface Plasmon Resonance (SPR)

In collaboration with scientists at Amgen, Genedata applied AI to automate SPR data analysis within Genedata Screener. The workflow streamlines decision-making and improves labeling accuracy through the following steps:

• Triages raw sensorgrams to focus analysis on samples with sufficient binding
• Classifies each drug candidate using AI as best fit by either a kinetic or steady-state binding model
• Flags ambiguous cases where no clear model applies, preventing misclassification and preserving data integrity
• Uses only high-confidence, accurately labeled data in downstream analysis to maintain consistency and reliability

This AI-driven workflow selects the correct model in over 90% of cases and clearly flags ambiguous results, ensuring that only high-confidence, accurately labeled data are used in downstream analysis, improving consistency, objectivity, and scalability.

Image-Based Screening (HCS)

Genedata’s Imagence solution automates training data curation for image-based screening, enabling cellular biologists to apply AI-powered analysis without programming expertise. Unlike traditional AI methods that require scripting and manual parameter tuning, Imagence simplifies image-based screening by performing the following actions:

• Eliminates the need for coding through a highly intuitive interface
• Defines phenotype sets automatically to train deep neural networks
• Classifies images across entire production-level screens
• Deploys models across multiple therapeutic areas and discovery stages without specialized technical support

This approach has enabled organizations such as AstraZeneca to scale phenotypic screening efficiently, reduce failed curves in dose-response assays, and analyze targets lacking a single, well-defined biomarker: unlocking the full potential of phenotypic screening.

Mass Spectrometry (MS)

In collaboration with Merck, Genedata automated a complex and time-intensive MS data processing workflow in Genedata Screener. The resulting pipeline performs the following steps to streamline analysis and improves consistency:

• Quantifies spectra automatically to ensure consistent signal interpretation
• Extracts numerical values from raw signals for downstream analysis
• Processes signals and identifies peaks with high precision
• Clusters data and performs final result quantification
• Applies a secure, customizable template to tailor analysis to specific assay designs

The automated workflow frees scientists to focus on discovery, eliminates interpretation bias, and ensures consistent, high-quality results across experiments.

Automation Enables Scalable, High-Quality Science

These examples show that even the most complex assays, involving rigorous quality control, validation, and decision-making, can be automated to deliver scientifically sound outcomes at scale. Genedata develops solutions that integrate advanced analytical methods into practical, easy-to-use workflows that accelerate discovery, enforce best practices, and drive innovation through consistency and reproducibility.